Search
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigationalBCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases. … [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideObeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalhepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation. … [A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or
Ticlopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is an effective inhibitor of platelet aggregation. … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.
Categories: Metabolic Side Effects of Drugs and SubstancesAdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalThe AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553]. … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawn[L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981. … [L1137] The radiopharmaceuticals based on technetium-99m are widely used for diagnostic purposes because 99mTc has a versatile chemistry which allows it to produce an extense variety of complexes with
Ceftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnUnion primarily due to data quality issues in pivotal clinical studies. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other … Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).
Seletracetam
go.drugbank.com/drugs/DB05885InvestigationalFood and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007. … As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam.
Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.
Synonyms: enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitorBismuth subgallate
go.drugbank.com/drugs/DB13909ApprovedPossessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter … It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed.